Researchers at Western University's Schulich School of Medicine & Dentistry have identified a potential pathway to reversing liver fibrosis, a condition that can lead to severe scarring and life-threatening liver disease. The study, published in Science Advances, reveals how specialized immune cells called mucosa-associated invariant T cells (MAIT cells) contribute to liver scarring and how targeting them could help mitigate or reverse the damage, according to a university news release.

Liver fibrosis occurs when ongoing damage from toxins, viral infections like COVID-19, metabolic stress, or autoimmune diseases causes a buildup of scar tissue. In the liver, excessive scar tissue can disrupt blood flow and impair organ function. If left unchecked, fibrosis can progress to cirrhosis, a severe form of scarring that is life-threatening. According to the Government of Canada, liver disease and cirrhosis were among the top 10 leading causes of death in Canada in 2024.

"There is an unmet need for early interventions to reverse fibrogenic processes before it is too late," said Mansour Haeryfar, a professor of immunology at Schulich Medicine & Dentistry and the study's lead author, as quoted in the release.

The research, led by Haeryfar and Nicole Ilayda Wang, a PhD candidate in microbiology and immunology, used preclinical mouse models and data from human patients with fibrosis to investigate MAIT cells' role in liver scarring. They discovered an interaction between MAIT cells and regulatory T cells, which normally help keep inflammation under control. The findings showed that MAIT cells worsen fibrosis by inhibiting regulatory T cells.

"MAIT cells are best known for their antimicrobial properties. However, we found them to be pathogenic in this context," said Haeryfar. "Mechanistically, they reduce regulatory T lymphocyte numbers in the liver, worsening fibrosis."

The study is the first to explain the exact role MAIT cells play in fibrogenic processes, the researchers said. It also demonstrates that therapeutically targeting MAIT cells by inhibiting their activity can reduce liver fibrosis, but only if intervention occurs in the very earliest stages of the disease.

"Our findings suggest that timing is critical, as targeting these cells early in the course of disease development may be particularly important for achieving therapeutic benefits," said Wang.

"Traditionally, MAIT cells have been studied primarily for their ability to fight infections, but much less was known about their roles in tissue injury, repair and scarring," Wang added. "Our findings reveal a previously underappreciated role for these cells in chronic liver disease and fibrosis development."

A better understanding of MAIT cells could also help researchers develop treatments for other diseases, including cancer, where these immune cells play different roles. "There is growing interest in treatments that use the immune system to fight disease. In cancer, for example, the goal is to help immune cells attack tumours," said Wang.

For university students studying health sciences, immunology, or medicine, this research highlights a promising new avenue for treating a common and serious condition. It also underscores the importance of early intervention in disease progression, a concept relevant across many fields of healthcare. The findings are based on preclinical models and patient data, so further research and clinical trials will be needed before any treatments become available.